The value of18F-fluorodeoxyglucose positron emission tomography/computed tomography for staging of primary extranodal head and neck lymphomas

Laryngoscope

Volumn 120, Issue 5, 2010, Pages 937-944

  Schrepfer, Thomas ^a   Haerle, Stephan K ^a   Strobel, Klaus ^a   Schaefer, Niklaus ^c   Hälg, Roger A ^b   Huber, Gerhard F ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fluorine 18 fluorodeoxyglucose positron emission tomography computed tomography; Head and neck; Initial staging; Lymphoma

Indexed keywords

BARIUM SULFATE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER LOCALIZATION; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CECUM CARCINOMA; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CYTOPATHOLOGY; DRUG UPTAKE; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEAD AND NECK CANCER; HEAD AND NECK DISEASE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; LOG RANK TEST; MALE; MAXIMUM STANDARDIZED UPTAKE VALUE; MEDICAL RECORD REVIEW; PALATINE TONSIL; PAROTIDECTOMY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RATING SCALE; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; T CELL LYMPHOMA; WALDEYER RING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BLOOD GLUCOSE; CECAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LYMPHOMA, LARGE B-CELL, DIFFUSE; LYMPHOMA, T-CELL; MALE; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, SECOND PRIMARY; OTORHINOLARYNGOLOGIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77951728696     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20843     Document Type: Article

References (26)

1. Newton R, Ferlay J, Beral V, Devesa S. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites. Int J Cancer 1997;72:923-930. (Pubitemid 27433552)
2. DePena C, Van Tassel P, Lee Y. Lymphoma of the head and neck. Radiol Clin North Am 1990;28:723-743.
3. Laskar S, Mohindra P, Gupta S, Shet T, Muckaden M. Non-Hodgkin lymphoma of the Waldeyer's ring: clinicopathologic and therapeutic issues. Leuk Lymphoma 2008;49:2263-2271.
4. Mohammadianpanah M, Omidvai S, Mosalei A, Ahmadloo N. Treatment results of tonsillar lymphoma: a 10-year experience. Ann Hematol 2005;84:223-226. (Pubitemid 40425067)
5. AlShemmari S, Ameen R, Sajnani K. Extranodal lymphoma: a comparative study. Hematology 2008;13:163-169.
6. Ezzat A, Ibrahim E, El Weshi A, et al. Localized non-Hodgkin's lymphoma of Waldeyer's ring: clinical features, management, and prognosis of 130 adult patients. Head Neck 2001;23:547-558. (Pubitemid 32565528)
7. Park Y, Lee J, Ryu M, et al. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients. Ann Hematol 2006;85:257-262. (Pubitemid 43298672)
8. Coiffier B, Reyes F. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Oncology (Williston Park) 2005;19(4 suppl 1):7-15.
9. Coiffier B. Current strategies for the treatment of diffuse large B cell lymphoma. Curr Opin Hematol 2005;12:259-265.
10. Coiffier B. Treatment of diffuse large B-cell lymphoma. Curr Hematol Rep 2005;4:7-14.
11. Schaefer N, Hany T, Taverna C, et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT? Radiology 2004;232:823-829.
12. Yang D, Min J, Jeong Y, et al. The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma. Ann Hematol 2009;88:425-432.
13. Zinzani P, Magagnoli M, Chierichetti F, et al. The role of positron emission tomography (PET) in the management of lymphoma patients. Ann Oncol 1999;10:1181-1184. (Pubitemid 29533567)
14. Zinzani P, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004;91:850-854. (Pubitemid 39273774)
15. Lin C, Itti E, Haioun C, et al. Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis. J Nucl Med 2007;48:1626-1632. (Pubitemid 47572710)
16. Itti E, Lin C, Dupuis J, et al. Prognostic value of interim 18F-FDG PET in patients with diffuse large B-cell lymphoma: SUV-based assessment at 4 cycles of chemotherapy. J Nucl Med 2009;50:527-533.
17. Krol A, le Cessie S, Snijder S, Kluin-Nelemans J, Kluin P, Noordijk E. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003;14:131-139. (Pubitemid 36150271)
18. R Development Core Team 2009, Version 2.8.1, R: A Language and Environment for Statistical Computing, Vienna, Austria, (http://www.R-project. org), ISBN 3-900051-07-0.
19. Byun B, Na I, Cheon G, et al. Clinical significance of 18FFDG uptake by primary sites in patients with diffuse large B cell lymphoma in the head and neck: a pilot study. Ann Nucl Med 2008;22:645-651.
20. Isasi C, Lu P, Blaufox M. A metaanalysis of 18F-2-deoxy-2-fluoro-D- glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 2005;104:1066-1074. (Pubitemid 41170236)
21. Fletcher J, Djulbegovic B, Soares H, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508. (Pubitemid 351355215)
22. Hutchings M, Eigtved A, Specht L. FDG-PET in the clinical management of Hodgkin lymphoma. Crit Rev Oncol Hematol 2004;52:19-32. (Pubitemid 39195242)
23. Hutchings M, Barrington S. PET/CT for therapy response assessment in lymphoma. J Nucl Med 2009;50(suppl 1):21S-30S.
24. Thie J, Hubner K, Smith G. The diagnostic utility of the lognormal behavior of PET standardized uptake values in tumors. J Nucl Med 2000;41:1664-1672.
25. Thie J. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med 2004;45:1431-1434. (Pubitemid 47618494)
26. Strobel K, Haerle S, Stoeckli S, et al. Head and neck squamous cell carcinoma (HNSCC)-detection of synchronous primaries with (18)F-FDG-PET/CT. Eur J Nucl Med Mol Imaging 2009;36:919-927.